• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在前列腺癌诊断和预后中实现准确蛋白质生物标志物的道路上：现状与未来进展。

On the Road to Accurate Protein Biomarkers in Prostate Cancer Diagnosis and Prognosis: Current Status and Future Advances.

机构信息

Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

出版信息

Int J Mol Sci. 2021 Dec 17;22(24):13537. doi: 10.3390/ijms222413537.

DOI:10.3390/ijms222413537
PMID:34948334
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8703658/
Abstract

Prostate cancer (PC) is a leading cause of morbidity and mortality among men worldwide. Molecular biomarkers work in conjunction with existing clinicopathologic tools to help physicians decide who to biopsy, re-biopsy, treat, or re-treat. The past decade has witnessed the commercialization of multiple PC protein biomarkers with improved performance, remarkable progress in proteomic technologies for global discovery and targeted validation of novel protein biomarkers from clinical specimens, and the emergence of novel, promising PC protein biomarkers. In this review, we summarize these advances and discuss the challenges and potential solutions for identifying and validating clinically useful protein biomarkers in PC diagnosis and prognosis. The identification of multi-protein biomarkers with high sensitivity and specificity, as well as their integration with clinicopathologic parameters, imaging, and other molecular biomarkers, bodes well for optimal personalized management of PC patients.

摘要

前列腺癌（PC）是全球男性发病率和死亡率的主要原因之一。分子生物标志物与现有的临床病理工具一起使用，以帮助医生决定对哪些患者进行活检、再次活检、治疗或重新治疗。在过去的十年中，已经商业化了多种具有改进性能的 PC 蛋白生物标志物，在蛋白质组学技术方面取得了显著进展，可从临床标本中发现和靶向验证新型蛋白生物标志物，并且出现了新的有前途的 PC 蛋白生物标志物。在这篇综述中，我们总结了这些进展，并讨论了在 PC 诊断和预后中识别和验证临床有用的蛋白生物标志物所面临的挑战和潜在解决方案。具有高灵敏度和特异性的多蛋白生物标志物的鉴定，以及与临床病理参数、影像学和其他分子生物标志物的整合，为 PC 患者的最佳个性化管理提供了良好的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/0668a4f3bb7b/ijms-22-13537-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/b26a36cc1d11/ijms-22-13537-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/6e432a468fd5/ijms-22-13537-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/3307dbc3ceed/ijms-22-13537-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/ecc83b7f11af/ijms-22-13537-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/e150dca42cda/ijms-22-13537-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/31d603ca7279/ijms-22-13537-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/7fa239b700a7/ijms-22-13537-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/0668a4f3bb7b/ijms-22-13537-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/b26a36cc1d11/ijms-22-13537-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/6e432a468fd5/ijms-22-13537-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/3307dbc3ceed/ijms-22-13537-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/ecc83b7f11af/ijms-22-13537-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/e150dca42cda/ijms-22-13537-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/31d603ca7279/ijms-22-13537-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/7fa239b700a7/ijms-22-13537-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a41/8703658/0668a4f3bb7b/ijms-22-13537-g008.jpg

相似文献

1
On the Road to Accurate Protein Biomarkers in Prostate Cancer Diagnosis and Prognosis: Current Status and Future Advances.在前列腺癌诊断和预后中实现准确蛋白质生物标志物的道路上：现状与未来进展。
Int J Mol Sci. 2021 Dec 17;22(24):13537. doi: 10.3390/ijms222413537.
2
Proteomics in diagnosis of prostate cancer.蛋白质组学在前列腺癌诊断中的应用
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015;36(1):5-36.
3
Proteomics approach to identify novel metastatic bone markers from the secretome of PC-3 prostate cancer cells.蛋白质组学方法从PC-3前列腺癌细胞分泌组中鉴定新型转移性骨标志物。
Electrophoresis. 2017 Oct;38(20):2638-2645. doi: 10.1002/elps.201700052. Epub 2017 Jul 10.
4
Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry.使用质谱法对局限性前列腺癌进行非侵入性生物标志物的蛋白质组学发现。
Nat Rev Urol. 2021 Dec;18(12):707-724. doi: 10.1038/s41585-021-00500-1. Epub 2021 Aug 27.
5
Proteomics in prostate cancer biomarker discovery.前列腺癌生物标志物发现中的蛋白质组学。
Expert Rev Proteomics. 2010 Feb;7(1):93-102. doi: 10.1586/epr.09.89.
6
Urinary biomarkers in prostate cancer detection and monitoring progression.用于前列腺癌检测和监测病情进展的尿液生物标志物。
Crit Rev Oncol Hematol. 2017 Oct;118:15-26. doi: 10.1016/j.critrevonc.2017.08.002. Epub 2017 Aug 19.
7
Biomarkers for the detection and prognosis of prostate cancer.用于前列腺癌检测和预后的生物标志物。
Curr Urol Rep. 2005 May;6(3):171-6. doi: 10.1007/s11934-005-0004-7.
8
Advances in proteomic prostate cancer biomarker discovery.蛋白质组学在前列腺癌生物标志物发现中的进展。
J Proteomics. 2010 Sep 10;73(10):1839-50. doi: 10.1016/j.jprot.2010.04.002. Epub 2010 Apr 14.
9
Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.锌 α2-糖蛋白作为一种潜在的新型尿液生物标志物用于前列腺癌的早期诊断。
BJU Int. 2012 Dec;110(11 Pt B):E688-93. doi: 10.1111/j.1464-410X.2012.11501.x. Epub 2012 Sep 28.
10
Recent progress and perspectives on prostate cancer biomarkers.前列腺癌生物标志物的最新进展与展望
Int J Clin Oncol. 2017 Apr;22(2):214-221. doi: 10.1007/s10147-016-1049-y. Epub 2016 Oct 11.

引用本文的文献

1
Proteomics Reveals Age as Major Modifier of Inflammatory CSF Signatures in Multiple Sclerosis.蛋白质组学揭示年龄是多发性硬化症炎症性 CSF 特征的主要修饰因子。
Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200322. doi: 10.1212/NXI.0000000000200322. Epub 2024 Nov 13.
2
Proteomic Signatures of Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Narrative Review.与新冠病毒相关的儿童多系统炎症综合征（MIS-C）的蛋白质组学特征：一项叙述性综述
Children (Basel). 2024 Sep 26;11(10):1174. doi: 10.3390/children11101174.
3
Transcriptome Data Reveal Geographic Heterogeneity in Gene Expression in Patients with Prostate Cancer.

本文引用的文献

1
Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk.大规模血浆蛋白质组分析鉴定出与痴呆风险相关的蛋白质和途径。
Nat Aging. 2021 May;1(5):473-489. doi: 10.1038/s43587-021-00064-0. Epub 2021 May 14.
2
Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer.一种用于指导临床显著性前列腺癌诊断活检决策的新型多变量风险评分的开发与验证。
BJUI Compass. 2020 Mar 12;1(1):15-20. doi: 10.1002/bco2.8. eCollection 2020 Mar.
3
Advances and Utility of the Human Plasma Proteome.
转录组数据揭示前列腺癌患者基因表达的地理异质性。
Rep Biochem Mol Biol. 2023 Apr;12(1):92-101. doi: 10.52547/rbmb.12.1.92.
4
Prognostic value of cell division cycle-associated protein-3 in prostate cancer.细胞分裂周期相关蛋白 3 在前列腺癌中的预后价值。
Medicine (Baltimore). 2023 Sep 8;102(36):e34655. doi: 10.1097/MD.0000000000034655.
5
Advancements in MRI-Based Radiomics and Artificial Intelligence for Prostate Cancer: A Comprehensive Review and Future Prospects.基于磁共振成像的放射组学和人工智能在前列腺癌中的进展：全面综述与未来展望
Cancers (Basel). 2023 Jul 28;15(15):3839. doi: 10.3390/cancers15153839.
6
Identification of candidate hub genes correlated with the pathogenesis, diagnosis, and prognosis of prostate cancer by integrated bioinformatics analysis.通过综合生物信息学分析鉴定与前列腺癌发病机制、诊断和预后相关的候选枢纽基因。
Transl Cancer Res. 2022 Oct;11(10):3548-3571. doi: 10.21037/tcr-22-703.
7
From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer.从组学到多组学方法深入分析前列腺癌的分子机制。
Int J Mol Sci. 2022 Jun 3;23(11):6281. doi: 10.3390/ijms23116281.
人类血浆蛋白质组学的进展与应用。
J Proteome Res. 2021 Dec 3;20(12):5241-5263. doi: 10.1021/acs.jproteome.1c00657. Epub 2021 Oct 21.
4
Uncovering the Depths of the Human Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein Detection and Quantification.揭示人类蛋白质组的深度：基于抗体的超高灵敏度多重蛋白质检测和定量技术。
Mol Cell Proteomics. 2021;20:100155. doi: 10.1016/j.mcpro.2021.100155. Epub 2021 Sep 28.
5
Identifying cancer drivers.鉴定致癌基因。
Science. 2021 Oct;374(6563):38-39. doi: 10.1126/science.abl9080. Epub 2021 Sep 30.
6
Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions.用于检测具有临床意义的前列腺癌的生物标志物：当代临床数据与未来方向。
Transl Androl Urol. 2021 Jul;10(7):3091-3103. doi: 10.21037/tau-20-1151.
7
Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine.前列腺癌精准医学中的组织和液体生物标志物
J Pers Med. 2021 Jul 15;11(7):664. doi: 10.3390/jpm11070664.
8
Nomogram Predicting Downgrading in National Comprehensive Cancer Network High-risk Prostate Cancer Patients Treated with Radical Prostatectomy.列线图预测接受根治性前列腺切除术治疗的美国国家综合癌症网络高危前列腺癌患者的降级。
Eur Urol Focus. 2022 Sep;8(5):1133-1140. doi: 10.1016/j.euf.2021.07.008. Epub 2021 Jul 30.
9
Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer.血清衍生细胞外囊泡的蛋白质组学分析在前列腺癌中的诊断和预后潜力。
Cell Death Dis. 2021 Jun 21;12(7):636. doi: 10.1038/s41419-021-03909-z.
10
Chemical isotope labeling for quantitative proteomics.化学同位素标记定量蛋白质组学。
Mass Spectrom Rev. 2023 Mar;42(2):546-576. doi: 10.1002/mas.21709. Epub 2021 Jun 6.